DLBCL Clinical Trials in Beijing, Beijing Municipality
6 recruitingBeijing, Beijing Municipality, China
Showing 1–6 of 6 trials
Recruiting
Phase 2Phase 3
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
DLBCL
Merck Sharp & Dohme LLC290 enrolled121 locationsNCT05139017
Recruiting
Phase 1Phase 2
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Non-Hodgkin LymphomaMantle Cell LymphomaFollicular Lymphoma+6 more
BeiGene146 enrolled29 locationsNCT05294731
Recruiting
Glofitamab in Chinese Patients With R/R DLBCL
DLBCL - Diffuse Large B Cell Lymphoma
Peking Union Medical College Hospital20 enrolled1 locationNCT06481826
Recruiting
Phase 2
Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination.
Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Daihong Liu30 enrolled1 locationNCT07489989
Recruiting
Phase 2
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)
Guangzhou Lupeng Pharmaceutical Company LTD.150 enrolled41 locationsNCT07189065
Recruiting
Phase 1Phase 2
A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)
Advanced Solid TumorDLBCL
Ranok Therapeutics (Hangzhou) Co., Ltd.32 enrolled5 locationsNCT05487170